Literature DB >> 20136851

Pediatric interventional cardiology in the United States is dependent on the off-label use of medical devices.

Jamie S Sutherell1, Russel Hirsch, Robert H Beekman.   

Abstract

OBJECTIVE: A substantial unmet medical device need exists in pediatric care. As a result, the off-label use of approved devices is routine in pediatric interventional cardiology, but the extent and nature of this practice has not been previously described. The purpose of this study, therefore, is to evaluate the prevalence and nature of off-label cardiac device use in an active pediatric interventional program in the United States. STUDY
DESIGN: This study is a retrospective review of all interventional cardiac procedures performed at our institution from July 1, 2005 to June 30, 2008. Diagnostic (noninterventional) catheterizations, myocardial biopsies, invasive electrophysiology studies, and studies involving investigational devices were excluded. Interventions performed were compared with the manufacturer's labeled indications for each device.
RESULTS: During this 3-year period, 473 patients (median age 4.1 years) underwent 595 transcatheter interventions. An approved device was utilized for an off-label application in 63% of patients, and in 50% of all interventions performed. The most frequent off-label procedures were stent implantations (99% off-label), balloon dilations (78% off-label), and coil embolizations (29% off-label). In contrast, the off-label use of septal and ductal occluders was relatively uncommon.
CONCLUSIONS: In our routine (noninvestigational) practice of pediatric interventional cardiology, 63% of patients underwent procedures utilizing medical devices for off-label indications. These data underscore the need to enhance cardiac device review and approval processes in the United States to include pediatric applications.

Entities:  

Mesh:

Year:  2010        PMID: 20136851     DOI: 10.1111/j.1747-0803.2009.00364.x

Source DB:  PubMed          Journal:  Congenit Heart Dis        ISSN: 1747-079X            Impact factor:   2.007


  17 in total

1.  The FDA Review Process for Cardiac Medical Devices in Children: A Review for the Clinician.

Authors:  Christopher S Almond
Journal:  Prog Pediatr Cardiol       Date:  2012-03-27

2.  Pediatric cardiovascular device registries--the need for such data and the potential impact.

Authors:  Francesca Joseph
Journal:  J Cardiovasc Transl Res       Date:  2010-06-29       Impact factor: 4.132

Review 3.  Paediatric cardiovascular clinical trials: an analysis of ClinicalTrials.gov and the Food and Drug Administration Pediatric Drug Labeling Database.

Authors:  Kevin D Hill; Heather T Henderson; Christoph P Hornik; Jennifer S Li
Journal:  Cardiol Young       Date:  2015-08       Impact factor: 1.093

4.  Enhanced endothelialization on surface modified poly(L-lactic acid) substrates.

Authors:  Hao Xu; Rajendrasing Deshmukh; Richard Timmons; Kytai Truong Nguyen
Journal:  Tissue Eng Part A       Date:  2010-12-18       Impact factor: 3.845

Review 5.  Post-market surveillance to detect adverse events associated with Melody® valve implantation.

Authors:  Kevin D Hill; Bryan H Goldstein; Michael J Angtuaco; Patricia Y Chu; Gregory A Fleming
Journal:  Cardiol Young       Date:  2016-11-10       Impact factor: 1.093

6.  Prevalence and Perioperative Outcomes of Off-Label Total Hip and Knee Arthroplasty in the United States, 2000-2010.

Authors:  Tennison Malcolm; Caleb R Szubski; Nicholas K Schiltz; Alison K Klika; Siran M Koroukian; Wael K Barsoum
Journal:  J Arthroplasty       Date:  2015-05-19       Impact factor: 4.757

7.  Regulator Loss Functions and Hierarchical Modeling for Safety Decision Making.

Authors:  Laura A Hatfield; Christine M Baugh; Vanessa Azzone; Sharon-Lise T Normand
Journal:  Med Decis Making       Date:  2017-01-23       Impact factor: 2.583

8.  US Food and Drug Administration Approval of High-risk Cardiovascular Devices for Use in Children and Adolescents, 1977-2021.

Authors:  Susmitha Wunnava; Timothy A Miller; Claire Narang; Meena Nathan; Florence T Bourgeois
Journal:  JAMA       Date:  2022-08-09       Impact factor: 157.335

9.  Postmarketing trials and pediatric device approvals.

Authors:  Thomas J Hwang; Aaron S Kesselheim; Florence T Bourgeois
Journal:  Pediatrics       Date:  2014-04-14       Impact factor: 7.124

10.  Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications.

Authors:  Samuel J Lee; Lauren Cho; Eyal Klang; James Wall; Stefano Rensi; Benjamin S Glicksberg
Journal:  JAMA Netw Open       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.